title: Theranostic Applications of Lutetium-177 in Radionuclide Therapy.
abstract: Lutetium-177 has been widely discussed as a radioisotope of choice for targeted radionuclide therapy. The simultaneous emission of imageable gamma photons [208 keV (11%) and 113 keV (6.4%)] along with particulate β(-) emission [β(max) = 497 keV] makes it a theranostically desirable radioisotope. In the present article, the possibility of using two 177Lu-based agents viz. 177Lu-EDTMP and 177Lu-DOTATATE for theranostic applications in metastatic bone pain palliation (MBPP) and peptide receptor radionuclide therapy (PRRT), have been explored. In the case of 177Lu-EDTMP, the whole-body images obtained are compared with those recorded using 99mTc-MDP in the same patient. On the other hand, pre-therapy images acquired with 177Lu-DOTA-TATE are compared with similar images obtained with standard agents, such as 99mTc-HYNIC-TOC (SPECT) and 68Ga-DOTA-TOC (PET) in the same patient. The advantage of the long physical half-life (T1/2) of 177Lu has been utilized in mapping the pharmacokinetics of two additional agents, 177Lu-labeled hydroxyapatite (HA) in radiation synovectomy of knee joints and 177Lu-HA for therapy of hepatocellular carcinoma. Results of these multiple studies conclusively document the potential of 177Lu as a theranostic radioisotope.
authors.forename: Tapas
authors.initials: T
authors.lastname: Das
authors.affiliation: Radiopharmaceuticals Chemistry Section, Radiochemistry &amp; Isotope Group, Bhabha Atomic Research Centre, Mumbai 400 085, India. sharmila@barc.gov.in.
authors.forename: Sharmila
authors.initials: S
authors.lastname: Banerjee
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D017886:Durapatite / Q000008:administration & dosage; D006207:Half-Life; D006801:Humans; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010146:Pain / Q000209:etiology / Q000532:radiotherapy; D011868:Radioisotopes / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics; D018000:Receptors, Peptide / Q000378:metabolism; D000068936:Theranostic Nanomedicine / Q000379:methods*
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; C119503:lutetium ethylenediaminetetramethylene phosphonic acid; D017886:Durapatite; C447941:lutetium Lu 177 dotatate; D015282:Octreotide